Featured Story

  • Pfizer's Prevenar price cut 'inadequate,' critics say

    Last week, international charity Médecins Sans Frontières called on Pfizer to drop its price on pneumococcal vaccine Prevenar 13. The pharma giant responded earlier this week, lopping 20 cents off the per-dose cost through vaccine alliance GAVI. But the way MSF sees it, that's not good enough. Read more >>

With 77 layoffs, Valeant gets to work squeezing costs from Dendreon

It's no secret that when serial acquirer and cost-cutting enthusiast Valeant takes over a company, layoffs are on the way. And for Dendreon, the bankrupt Seattle biotech whose assets the Canadian snatched up last month, they've already begun.

Aduro to start Phase II trial of cancer vaccine combo with BMS' Opdivo

In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that it would start a Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb PD-1 drug.

Valeant touts PhII Provenge data following Dendreon buy

Valeant only just picked up Provenge and other assets from bankrupt Dendreon, but it's already trumpeting positive preliminary data for the flailing cancer vaccine. On Wednesday, it announced Phase II results showing that the immune response from Provenge continues two years after biochemically recurrent prostate cancer patients complete treatment.

NewLink nets $20M Ebola milestone from Merck

NewLink's Ebola vaccine tie-up with Merck continues to pay off.

Combo of Bavarian Nordic's Prostvac and BMS' Yervoy yields promising PhI results

On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.


From Our Sister Sites


Laboratory equipment and services company PerkinElmer announced that it will provide Johnson & Johnson's new San Francisco life science incubator with on-site staff, training and scientific application support.


The FDA has issued a Class 2 recall notice for an electrophysiology cardiac catheter from Biosense Webster, which is a Johnson & Johnson company, due to difficulties with retraction. The recall covers the Lasso NAV Duo Loop eco Catheters. Biosense Webster is the top-performing J&J medical device group as electrophysiology has gained traction of late.